Pacific Biosciences Of California vs Quanterix
Pacific Biosciences Of California is the larger business, with $160m of revenue in fiscal 2025 against $139m for Quanterix (1.2 times as much). Pacific Biosciences Of California grew faster (3.9% against 1.1%). Quanterix kept more of each dollar of sales as profit: a net margin of -77.1% against -341.5%.
| Latest fiscal year | Pacific Biosciences Of CaliforniaPACB, 2025 | QuanterixQTRX, 2025 |
|---|---|---|
| Revenue | $160m | $139m |
| Revenue growth | 3.9% | 1.1% |
| Net income | −$546m | −$107m |
| Operating margin | -346.2% | — |
| Net margin | -341.5% | -77.1% |
| Return on equity | — | -34.2% |
| Free cash flow | −$114m | −$79.8m |
| Cash | $63.7m | $29.8m |
| Total debt | $645m | $0 |
| Debt to equity | 12065.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 485 | 450 |
| Market value | $763m | $137m |
| Price vs our value range | — | — |
| Moat score | 13 (Weak) | 18 (Weak) |
| Insider trades, 12 months | 0 buys, 12 sales | 3 buys, 0 sales |